Smartleaf Asset Management LLC Cuts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Smartleaf Asset Management LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 752 shares of the company’s stock after selling 171 shares during the period. Smartleaf Asset Management LLC’s holdings in Medpace were worth $251,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. Centaurus Financial Inc. raised its holdings in shares of Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares in the last quarter. Schulhoff & Co. Inc. increased its holdings in Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after buying an additional 30 shares during the period. Lindenwold Advisors INC raised its stake in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after buying an additional 32 shares in the last quarter. Stephens Inc. AR lifted its holdings in Medpace by 4.9% during the fourth quarter. Stephens Inc. AR now owns 752 shares of the company’s stock worth $250,000 after buying an additional 35 shares during the period. Finally, M&T Bank Corp boosted its position in Medpace by 1.2% during the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after acquiring an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Shares of MEDP stock opened at $328.56 on Thursday. The stock’s fifty day moving average price is $341.61 and its 200 day moving average price is $344.15. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The company has a market cap of $10.01 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.